Skip to main content
Top
Published in: Journal of General Internal Medicine 7/2021

01-07-2021 | Infliximab | Clinical Vignette

Infliximab-Induced Lupus Causing Pericarditis: a Case Report and Review of the Literature

Authors: Mrudula Thiriveedi, MD, Taylor D. Steuber, PharmD, Mohamed Hasan, MD, Alan Baggett, MD, FACP

Published in: Journal of General Internal Medicine | Issue 7/2021

Login to get access

Excerpt

A 49-year-old woman presented with a 1-day history of sharp left-sided pleuritic chest pain radiating to the back and associated with shortness of breath. Her past medical history was significant for fistulizing Crohn’s disease (CD) diagnosed in 2011, status post hemicolectomy. She was on prednisone intermittently over the first few years after diagnosis and reportedly had never been on aminosalicylates (mesalamine or sulfasalazine), thiopurines such as azathioprine or 6-mercaptopurine, or methotrexate. At the time of presentation, she was not taking prednisone or any other corticosteroids. She was started on infliximab therapy a year prior to admission and had initially received infusions every 8 weeks prior to switching to every 6 weeks. Additionally, she had missed her most recent dose that was due 3 weeks prior due to insurance issues, so it had been 9 weeks since her last dose. She denied any preceding viral prodromal symptoms including fever, chills, myalgia, headache, cough, rhinitis, nausea, or vomiting and also denied any previous sick contacts or recent travel. …
Literature
1.
go back to reference Lichtenstein GR, Loftus Jr EV, Isaacs KI, Regeuiro MD, Gerson LB, Sands BE. ACG clinical guideline: management of Crohn’s disease in adults. Am J Gastroenterol 2018; 113:481-517.CrossRef Lichtenstein GR, Loftus Jr EV, Isaacs KI, Regeuiro MD, Gerson LB, Sands BE. ACG clinical guideline: management of Crohn’s disease in adults. Am J Gastroenterol 2018; 113:481-517.CrossRef
2.
go back to reference Klotz U, Teml A, Schwab M. Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet 2007;46 (8):645-660.CrossRef Klotz U, Teml A, Schwab M. Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet 2007;46 (8):645-660.CrossRef
3.
go back to reference Adegbola SO, Sahnan K, Warusavitarne J, Hart A, Tozer P. Anti-TNF therapy in Crohn’s disease. Int J Mol Sci 2018;19 (8):2244.CrossRef Adegbola SO, Sahnan K, Warusavitarne J, Hart A, Tozer P. Anti-TNF therapy in Crohn’s disease. Int J Mol Sci 2018;19 (8):2244.CrossRef
4.
go back to reference Almoallim H, Al-Ghamdi Y, Almaghrabi H, Alyasi O. Anti-Tumor Necrosis Factor- Induced Systemic Lupus Erythematosus. Open Rheumatol J 2012;6:315-319.CrossRef Almoallim H, Al-Ghamdi Y, Almaghrabi H, Alyasi O. Anti-Tumor Necrosis Factor- Induced Systemic Lupus Erythematosus. Open Rheumatol J 2012;6:315-319.CrossRef
5.
go back to reference Ramos-Casals M, Roberto-Perez-Alvarez C, Cuadrado MJ, Khamashta MA. Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmun Rev 2010;9: 188–193.CrossRef Ramos-Casals M, Roberto-Perez-Alvarez C, Cuadrado MJ, Khamashta MA. Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmun Rev 2010;9: 188–193.CrossRef
6.
go back to reference Burke JP, Kelleher B, Ramadan S, Quinlan M, Sugrue D, O’Donovan MA. Pericarditis as a complication of infliximab therapy in Crohn’s disease. Inflamm Bowel Dis 2008;14 (3):428–429.CrossRef Burke JP, Kelleher B, Ramadan S, Quinlan M, Sugrue D, O’Donovan MA. Pericarditis as a complication of infliximab therapy in Crohn’s disease. Inflamm Bowel Dis 2008;14 (3):428–429.CrossRef
7.
go back to reference Perez-De-Lis M, Retamozo S, Florez-Chavez A, et al. Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry). Expert Opin Drug Saf 2017;16 (11):1255-1271.CrossRef Perez-De-Lis M, Retamozo S, Florez-Chavez A, et al. Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry). Expert Opin Drug Saf 2017;16 (11):1255-1271.CrossRef
8.
go back to reference Pereira VM, Andrade C, Figueira R, Faria G, Jasmins L. Infliximab-induced lupus: a case report. GE-Portuguese Journal of Gastroenterology 2017;24 (2):84–88.CrossRef Pereira VM, Andrade C, Figueira R, Faria G, Jasmins L. Infliximab-induced lupus: a case report. GE-Portuguese Journal of Gastroenterology 2017;24 (2):84–88.CrossRef
9.
go back to reference Mizra M, Mizra M, Murugesan V, Olano A. Pericardial effusion due to infliximab therapy for ulcerative colitis. Case Rep Gastrointest Med 2018; Article 4324592. Mizra M, Mizra M, Murugesan V, Olano A. Pericardial effusion due to infliximab therapy for ulcerative colitis. Case Rep Gastrointest Med 2018; Article 4324592.
10.
go back to reference Ramos-Casals M, Brito-Zeron P, Munoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine 2007; 86:242-251.CrossRef Ramos-Casals M, Brito-Zeron P, Munoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine 2007; 86:242-251.CrossRef
11.
go back to reference Costa MF, Said NR, Zimmermann B. Drug-induced lupus due to anti-tumor necrosis alpha agents. Semin Arthritis Rheum 2008;37 (6):381-387.CrossRef Costa MF, Said NR, Zimmermann B. Drug-induced lupus due to anti-tumor necrosis alpha agents. Semin Arthritis Rheum 2008;37 (6):381-387.CrossRef
12.
go back to reference Saddler K, Castro-Lainez MT, Deliz-Aguirre R, et al. Nontyphoidal Salmonella purulent pericarditis presenting with pericardial tamponade in a patient on infliximab therapy. IDCases 2019; 15: e00500.CrossRef Saddler K, Castro-Lainez MT, Deliz-Aguirre R, et al. Nontyphoidal Salmonella purulent pericarditis presenting with pericardial tamponade in a patient on infliximab therapy. IDCases 2019; 15: e00500.CrossRef
13.
go back to reference Naseer M, Kulairi Z, Kam M. Cardiac tamponade as a presenting manifestation of infliximab-induced lupus in patient treated for Crohn’s disease. ACG Case Rep 2017;4:e1.CrossRef Naseer M, Kulairi Z, Kam M. Cardiac tamponade as a presenting manifestation of infliximab-induced lupus in patient treated for Crohn’s disease. ACG Case Rep 2017;4:e1.CrossRef
14.
go back to reference Dipasquale V, Gramaglia SMC, Catena MA, Romano C. Pericarditis during infliximab therapy in paediatric ulcerative colitis. J Clin Pharm Ther 2018;43(1):107-109.CrossRef Dipasquale V, Gramaglia SMC, Catena MA, Romano C. Pericarditis during infliximab therapy in paediatric ulcerative colitis. J Clin Pharm Ther 2018;43(1):107-109.CrossRef
15.
go back to reference Lather HD, Henry D, Kahlenberg JM. Hemorrhagic pericardial effusion with tamponade: a rare adverse effect of infliximab-case report and literature review. Case Reports in Rheumatology 2016; Article: 2576496. Lather HD, Henry D, Kahlenberg JM. Hemorrhagic pericardial effusion with tamponade: a rare adverse effect of infliximab-case report and literature review. Case Reports in Rheumatology 2016; Article: 2576496.
16.
go back to reference Harnett DT, Chandra-Sekhar HB, Hamilton SF. Drug-induced lupus erythematosus presenting with cardiac tamponade: a case report and literature review. Can J Cardiol 2014; 30 (2):247.e11-2.CrossRef Harnett DT, Chandra-Sekhar HB, Hamilton SF. Drug-induced lupus erythematosus presenting with cardiac tamponade: a case report and literature review. Can J Cardiol 2014; 30 (2):247.e11-2.CrossRef
17.
go back to reference Nakamura Y, Izumi C, Nakagawa Y, Hatta K. A case of effusive–constrictive pericarditis accompanying rheumatoid arthritis: The possibility of adverse effect of TNF-inhibitor therapy J Cardiol Cases 2013;7 (1):e8-e10.CrossRef Nakamura Y, Izumi C, Nakagawa Y, Hatta K. A case of effusive–constrictive pericarditis accompanying rheumatoid arthritis: The possibility of adverse effect of TNF-inhibitor therapy J Cardiol Cases 2013;7 (1):e8-e10.CrossRef
18.
go back to reference Devasahayam J, Pillai U, Lacasse A. A rare case of pericarditis, complication of infliximab treatment for Crohn’s disease. Journal of Crohn’s and Colitis 2012;6(6):730-731.CrossRef Devasahayam J, Pillai U, Lacasse A. A rare case of pericarditis, complication of infliximab treatment for Crohn’s disease. Journal of Crohn’s and Colitis 2012;6(6):730-731.CrossRef
19.
go back to reference Harney S, O’Shea FD, Fitzgerald O. Peptostreptococcal pericarditis complicating anti-tumour necrosis factor α treatment in rheumatoid arthritis. Ann Rheum Dis 2002;61:653-654.CrossRef Harney S, O’Shea FD, Fitzgerald O. Peptostreptococcal pericarditis complicating anti-tumour necrosis factor α treatment in rheumatoid arthritis. Ann Rheum Dis 2002;61:653-654.CrossRef
20.
go back to reference Shahidi N, Bressler B, Panaccione R. The role of vedolizumab in patients with moderate-to-severe Crohn’s disease and ulcerative colitis. Therapy Adv Gastroenterol 2016;9(3):330–338.CrossRef Shahidi N, Bressler B, Panaccione R. The role of vedolizumab in patients with moderate-to-severe Crohn’s disease and ulcerative colitis. Therapy Adv Gastroenterol 2016;9(3):330–338.CrossRef
21.
go back to reference Colombel JF, Sands BE, Rutgeerts P, et al. The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut 2017;66 (5):839-851.CrossRef Colombel JF, Sands BE, Rutgeerts P, et al. The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut 2017;66 (5):839-851.CrossRef
Metadata
Title
Infliximab-Induced Lupus Causing Pericarditis: a Case Report and Review of the Literature
Authors
Mrudula Thiriveedi, MD
Taylor D. Steuber, PharmD
Mohamed Hasan, MD
Alan Baggett, MD, FACP
Publication date
01-07-2021
Publisher
Springer International Publishing
Published in
Journal of General Internal Medicine / Issue 7/2021
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-021-06781-x

Other articles of this Issue 7/2021

Journal of General Internal Medicine 7/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.